Abstract:Dysfunction or dysregulation of the ubiquitin proteasome system (UPS) is closely related to tumorigenesis and the development of multiple cancers. Targeting the UPS provides a new anticancer therapeutic strategy, but clinically available UPS-targeted inhibitors, including lenalidomide and bortezomib, are limited to treat solid tumors. Under physiological conditions, deubiquitinases or deubiquitinating enzymes (DUBs) play vital roles in the UPS by removing ubiquitin from substrate proteins and regulating their proteasomal degradation and sub-localization, thus maintaining the balance between ubiquitination and deubiquitination for protein quality control and homeostasis. The aberrant expression or function of DUBs generally leads to the occurrence and progression of a series of disorders, including malignant tumors. Therefore, targeting DUBs is a novel anticancer therapeutic strategy. Ubiquitin-specific proteases (USPs) are the largest subfamily of DUBs which have attracted considerable interest as anticancer targets. Most of USPs are abnormally activated or expressed in a variety of malignant tumors or in the tumor microenvironment, making them ideal anticancer target candidates, which indicates that USPs inhibitors may be a class of potential anticancer therapeutic agents. However, there are no relevant inhibitors targeting USPs have entered clinical trial so far. In this review, we will summarize the roles and mechanisms of USPs in malignant transformation and progression as well as recent advances of small-molecule inhibitors targeting USPs.

The ubiquitin-proteasome system in breast cancer

Ubiquitin–proteasome system (UPS) as a target for anticancer treatment

Ubiquitin-specific peptidase 22 in cancer

The Role Of The Ubiquitin-Proteasome Pathway In Cancer Development And Treatment

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Dysregulation of deubiquitination in breast cancer

The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy

Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

The Ubiquitin–proteasome System and Its Potential Application in Hepatocellular Carcinoma Therapy

The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Expanding the ubiquitin code in pancreatic cancer

Roles and Mechanisms of Deubiquitinases (dubs) in Breast Cancer Progression and Targeted Drug Discovery

Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application

The Ubiquitin–Proteasome System in Tumor Metabolism

The Ubiquitin System: Orchestrating Cellular Signals in Non-Small-cell Lung Cancer